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AbstrACt 
Introduction There is a lot of speculation about why 
and how patients decide to use invasive treatment in 
an advanced stage of cancer, but the body of research 
is limited. The present longitudinal qualitative and 
quantitative study reflects real-life practice of pixantrone 
use and aims to collect data on patients’ considerations 
for, expectations of and experiences with pixantrone and 
trajectories in their quality-of-life (QoL) values in a Dutch 
clinical setting. Hence, two questions emerge. Why do 
patients choose for this treatment, while the treatment 
success rate is limited and curation cannot be achieved? 
And second, once chosen, what conditions would patients 
like to satisfy and how do they experience the treatment?
Methods and analysis This is a non-interventional 
longitudinal and multicentre study. Patients are eligible 
if they are >18 years, have never been treated with 
pixantrone before, have an Eastern Cooperative Oncology 
Group performance score ≤2, have a relapsed or refractory 
diffuse large B-cell lymphoma and have been treated with 
at least two prior regimens. The decision to treat patients 
with pixantrone has been taken by the treating physician 
before patients are asked to participate in the study. If 
patients refuse study participation after being informed 
by the investigator, reasons for refusal (if given) will be 
recorded. Participants will receive at least three interviews 
accompanied by three QOL questionnaires. Based on the 
required sample size, we aim to include 20 patients over a 
period of 2 years.
Ethics and dissemination The Medical Ethical 
Committee of Erasmus MC, Rotterdam, The Netherlands, 
has approved this study. The results will be disseminated 
in peer-reviewed journals and major international 
conferences. The study is non-interventional and falls 
therefore not under Medical Research Involving Human 
Subjects Act (In Dutch: Wet medisch-wetenschappelijk 
onderzoek met mensen; WMO). Hence, this study is 
approved to be carried out in the Erasmus MC. Each 
other participating centre will receive this approval and 
will separately undergo the ethical approval to be able 
to participate. In addition to the ethical approval, the 
participating centres need to obtain written informed 
consent of their patients. Given the non-interventional 
nature of this study, a study registration was considered 
but deemed unnecessary. The study will be conducted in 
accordance with the Declaration of Helsinki (Tokyo, Venice, 
Hong Kong and Somerset West amendments). A sequential 
identification number will be automatically attributed to 
each patient that has given consent to participate in the 
study. This number will identify the patient and must be 
included on all documents. Only the main researcher can 
link the code to the patient’s identity. 
IntroduCtIon
There is a lot of speculation about why and 
how patients decide to use invasive treatment 
in an advanced stage of cancer, but the body 
of research is limited.1–3 In an advanced and 
incurable stage, patients and their family have 
to cope with difficult decisions on further 
treatment.4 A little increase in survival time 
must be weighed against the intensity of the 
treatment. A meaningful task of the health-
care system is to support decision-making for 
both physicians and patients. Experiences of 
other patients can be thought to be helpful 
in that respect.5 The present longitudinal 
strengths and limitations of this study
 ► The use of mixed methods for data collection.
 ► The present research reflects real-life practice of 
pixantrone use.
 ► Results will provide knowledge about patients’ rea-
soning in an advanced stage of cancer.
 ► Gaining a better understanding of treatment-related 
decision-making and treatment experiences could 
facilitate decision-making for future patients and 
doctors.
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mixed methods study reflects real-life practice of pixan-
trone use in patients with relapsed or refractory diffuse 
large B-cell lymphoma (DLBCL) and aims to collect data 
on the patients’ considerations for, expectations of and 
experiences with pixantrone and trajectories in their 
quality-of-life (QoL) values in a Dutch clinical setting.
In 2007, 1572 patients were diagnosed with aggressive 
non-Hodgkin’s lymphoma (NHL) in the Netherlands and 
it is expected that the incidence will increase to almost 
1900 patients in the year 2020 due to the ageing of the 
population.6 After NHL diagnosis and during its treat-
ments, patients’ health-related quality of life (HRQOL) 
can be affected in a negative way.7 For instance, NHL 
survivors reported significant worse psychological and 
physical HRQOL.8 New developments in treatment prac-
tices are therefore essential. Treatment with pixantrone 
(Pixuvri, Servier) is a new development, which is indi-
cated as monotherapy for the treatment of adult patients 
with DLBCL who have been previously treated with two or 
more regimens. Pixantrone, administered intravenously 
in the hospital, was developed to reduce the anthracy-
cline-associated cardiotoxicity while retaining efficacy. 
The drug, a novel cytotoxic aza-anthracenedione, has 
been proven to be efficacious in patients with relapsed or 
refractory aggressive B-cell lymphoma.9 10 Patients treated 
with pixantrone demonstrated an overall response rate 
of 37% compared with an overall response rate of 14% 
for patients treated with comparator agents. The progres-
sion-free survival for patients treated with pixantrone 
was 2.1 months longer compared with patients treated 
with comparator agents. Besides pixantrone, there is no 
approved substitute available. None of the drugs currently 
being evaluated show adequate potential as single agent 
in the treatment of patients with relapsed DLBCL inel-
igible for autologous stem cell transplant (ASCT). The 
drug is available on the market since fall 2014 and just 
recently included in the national guidelines for patients 
who undergo a third-line or fourth-line treatment for 
DLBCL.11 Therefore, in the Netherlands, a very small 
number of patients have so far been treated with this 
drug. Hence, no data are thus far reported regarding 
patients’ decision-making and experiences with this treat-
ment. Collecting and reporting of such data are the main 
objective of this study.
Treatment decision-making involves the evaluation of 
all available information, weighing the risks and benefits, 
personal preferences and eventually the selection of the 
best alternative. Information is one of the most important 
preconditions for participation in decision-making.12 
From a systematic review about information giving and 
decision-making in patients with advanced cancer,1 it is 
known that the need for information is often underes-
timated by the doctors. Moreover, informed decisions 
on further treatment cannot be made without knowing 
or understanding the actual prognosis. Adequate infor-
mation giving reduces anxiety, creates realistic expecta-
tions and gives a sense of control. Thus, it contributes to 
an increase in HRQOL. Patients’ preferences for being 
involved in decision-making differ from their desire 
for information, almost 66 per cent of patients in an 
end-of-life situation would like to be involved to a certain 
extent.6 13 But this may vary during the course of the 
disease: patients who become more ill usually want to pass 
control to the doctor,14 while those who have improved 
after the first treatment often want more involvement 
in subsequent decisions.6 Other relevant determinants 
are age, gender, socioeconomic status and education. 
Currently, the age at diagnosis for NHL is approximately 
66 years.15 On average, older patients with cancer prefer 
to receive less information about their disease and treat-
ment and prefer a less active role in making treatment 
decisions. They are also less likely to collect and analyse 
all relevant information in order to make an optimal deci-
sion.16 Older patients in Europe have, on average, a lower 
educational level than younger ones and therefore may be 
less confident in the results of treatments and less aware 
of medical innovations.17 Older people may also think 
that decision-making is the physicians’ responsibility.18 
When it comes to differences in gender, it seems that 
men prefer to play a less active role in decision-making 
than women.19 Patients from lower social classes are often 
disadvantaged because of the physicians’ misperception 
of their need for information and their ability to take part 
in the healthcare process.20 Another precondition for 
decision-making is patients’ competence.21 Competence 
contains the patient’s ability to understand that their 
choices have consequences. A competent person has 
the capacity to reach a reasonable decision by compre-
hending all relevant information and by weighing the 
benefits and the risks. Patients’ decision-making abilities 
may be negatively affected by fears, anxiety and difficulties 
in understanding the given information.22 Additionally, 
opinions of family members are also relevant.23 No data 
are yet available on differences between ethnic popula-
tions in comparable disease settings as patients for whom 
pixantrone is indicated on the target parameters of this 
study (decision-making, preferences and experiences). 
Therefore, we include both Western and non-Western 
patients and do not expect ethnic differences on the 
parameters under research. There also might be a differ-
ence between patients that start pixantrone treatment in a 
relative early disease setting (third-line treatment) versus 
those that start the treatment in a later disease setting 
(fourth line and later). Patients that start the treatment 
with pixantrone in late disease settings have inherently 
undergone more treatments which may make their deci-
sions, experiences and preferences regarding pixantrone 
treatment different compared with patients in relatively 
earlier disease settings.
Given the expected increase in NHL incidence rates 
due to the increasing average age and the speculations 
about why and how these patients decide to accept inva-
sive treatment, there is still much to be done to under-
stand patients’ reasoning in this advanced stage of 
cancer. The present research reflects real-life practice of 
pixantrone use and aims to collect data on the patients’ 
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considerations for, expectations of and experiences with 
pixantrone and trajectories in their QoL values in a Dutch 
clinical setting.
objectives
The primary objective of this non-interventional study is 
to qualitatively explore patients’ decision-making, expe-
riences and preferences regarding pixantrone treatment 
for their DLBCL. Hence, two questions emerge. Why do 
patients choose for this treatment, while the treatment 
success rate is limited and curation cannot be achieved? 
And second, once chosen, how do they experience the 
treatment? The secondary objective of this study is to 
assess changes in QOL among patients during their 
treatment for DLBCL with pixantrone. Since the QOL 
drops down over the course of the therapy, the expected 
QOL trajectory will be in a negative direction. Therefore, 
the changes in QOL values will be used to compare (1) 
patients that respond to treatment with pixantrone versus 
those that do not respond to treatment, (2) patients that 
start the drug treatment with pixantrone in third-line 
treatment versus those that start the treatment in the 
fourth line and later and (3) patients that show complete 
response to pixantrone within patient QOL value differ-
ences in the disease progression-free period versus the 
QOL value at the moment of disease progression.
MEthods And AnAlysIs
Patient and public involvement
Patients or public were not involved. Patient participation 
will be sought for two phases: (1) conducting research: 
agenda setting for patient and public involvement meet-
ings in collaboration with the research team and providing 
a governance function to ensure that researchers are 
acting responsibly; and (2) sharing and using research 
knowledge: sharing knowledge and learning about the 
research to other relevant stakeholders (eg, by giving 
verbal updates, writing reports, presenting at or attending 
conferences and meetings) and guiding the direction of 
future research. 
study population
Eligible patients are adults (>18 years) with a current 
diagnosis of relapsed or refractory DLBCL that have been 
treated with at least two prior lines of therapy, have never 
have been treated with pixantrone before and have an 
Eastern Cooperative Oncology Group performance status 
of 0–2.24 Patients who are participating in an (experi-
mental) drug trial other than pixantrone or those with 
an uncontrolled medical disease that could compromise 
patients’ safety will not be included. Although patients 
using pixantrone are scarce, we will strive to include at 
least 20 patients over a period of 2 years.
design and procedure
The purposive sample of 20 patients will be recruited from 
a wide range of tertiary care hospitals in The Netherlands 
due to the scarcity of the research population. Currently, 
the study is approved to be carried out in four medical 
centres. The decision to treat patients with pixantrone 
has been taken by the treating physician before patients 
are asked to participate in the study. The physician of the 
participating medical centre will inform the researcher 
when they are going to treat a patient with pixantrone. 
If a patient is willing to participate, the first author (LvH, 
junior researcher, MSc Neuropsychology, man) will invite 
him or her by telephone for the first interview. Participa-
tion is completely voluntary: subjects can leave the study 
at any time for any reason if they wish to do so without 
stating any reason and any consequences for their medical 
treatment (dropout). If they have a reason that they want 
to tell, it will be recorded. The participants are made 
aware of this in the patient information letter they receive 
before signing informed consent. All data collected up to 
the moment of dropout will be stored. If premature termi-
nation has taken place for reasons other than patient-ini-
tiated factors (eg, medical reasons, sudden death), a 
final measurement (interview +questionnaires) will take 
place, if the participant has not withdrawn consent for 
that reason. In case of a dropout, we will seek further to 
include more patients, within the possibilities of our time 
schedule. Those patients that participate will receive at 
least three interviews accompanied by three QOL ques-
tionnaires (see also figure 1). Measurement point T2 
will only consist of the three questionnaires. If a patient 
does not master the Dutch language, the use of a trans-
lated questionnaire or an interpreter for interviews will 
be considered and offered to the patient. Both the inter-
view techniques as the questionnaires are according to 
the standard clinical practice. The administration of both 
can take either place in the hospital or at the patient’s 
home. The choice of the study venue will be left to the 
patient, whichever is more comfortable for him or her. 
The patient may be accompanied by their spouse, another 
family member or caregiver during the interview. Those 
are classified as observers, and their input will not be used 
in data analysis. It is conceivable that patients become 
upset during the interview. Alongside the interviewer (SI, 
senior researcher, PhD Medical Science, man), a junior 
researcher (LvH) will be present. Both are well-trained 
psychologists and are instructed how to cope with such 
situation. During the interview, this junior researcher 
will ensure correct recording of the interview and will 
be taking paper and pencil notes (backup data). Both 
the interviewer and the junior researcher have adequate 
knowledge of qualitative methods based on previous 
research projects and education. The researchers have 
no prior relationship with the participants and all partic-
ipants will be provided with information about the study 
and the research team before starting the interviews. The 
interviews will approximately last 1 hour and an addi-
tional 15 min to complete the QOL questionnaires. Data 
collection is scheduled as follows (see also figure 1):
 ► T0=0–8 days prior to pixantrone treatment cycle 1: 
interview and questionnaires.
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 ► T1=3–4 weeks, between weeks 3 and 4 during 
pixantrone treatment cycle 1 (C1): interview and 
questionnaires.
 ► T2=7–8 weeks, between weeks 3 and 4 during 
pixantrone treatment cycle 2 (C2): questionnaires 
only.
 ► T3=11–12 weeks, between weeks 3 and 4 during 
pixantrone treatment cycle 3 (C3): interview and 
questionnaires.
In case of disease progression or treatment discon-
tinuation during C1–C3: the interview at T3 will be 
the last interview. For patients that show or remain in 
complete response, partial response or stable disease 
after C3 (approximately 20%–25%), the closing interview 
including questionnaires is planned at:
 ► T4=within week 1–2 after discontinuation of 
pixantrone due to disease progression or initiated by 
and at the discretion of the physician or the patient.
data collection
Qualitative interviews
Data from the interviews will be analysed according to the 
principles of grounded theory,25 26 which is aimed at the 
construction of theory grounded in the data from which it 
is developed. A more detailed description of this approach 
is explained in the next paragraph. This approach is 
chosen because of the lack of knowledge about patients’ 
decision-making, experiences and preferences regarding 
pixantrone treatment. To explore patients’ perspectives, 
semistructured interviews will be conducted. Interviews 
will be taped and transcribed verbatim and if necessary 
translated into Dutch. Tape recordings will be altered to 
remove identifying information. Interviews will be anony-
mised (person, place names, staff, family members). We 
do not plan to return the transcripts to participants for 
comments or corrections. There is no evidence that use 
of certain checks improves research quality where the 
primary purpose of the research is theory development.27 
The interview contains four major topics: decision-mak-
ing-related factors (eg, weighing pros and cons, the involve-
ment of others), treatment-related factors (eg, expectations 
about benefits and side effects), physician-related factors 
(eg, communication, trust in physician) and patient-re-
lated factors (eg, disease knowledge, treatment history). 
An additional file shows the topic list in more detail (see 
online supplementary additional file 1). This topic list is 
developed by the research team with reference to their 
previous projects and through discussion of the objectives 
and study aim.
The transcripts will first be coded using open coding. 
Next, these codes will be grouped into concepts after 
which the concepts will be piled into categories that cover 
all relevant information. To maximise efficiency and reli-
ability compared with paper and pencil analysis, the qual-
itative software programme NVivo (V.11) will be used for 
analysis. First, we will generate a grid according to Miles 
and Huberman’s method in order to be able to compare 
the data between the different time points.28 At least two 
independent researchers (LvH and SI) will read through 
the transcripts twice while listening to the tape record-
ings and organise them into a table. Words or phrases will 
be combined together in order to generate a covering 
category. This process goes on until the two researchers 
separately worked through the whole transcript and data 
saturation has been reached. The two researchers then 
will jointly cluster the derived categories into themes. 
Thereby, they will identify the underlying uniformities of 
the categories and further sharpen the conceptual struc-
ture of each theme. Finally, within each theme, responses 
Figure 1 Patients’ flow and measurement moments in the study.
 o
n
 7 August 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026505 on 22 May 2019. Downloaded from 
5van Hoogdalem LE, et al. BMJ Open 2019;9:e026505. doi:10.1136/bmjopen-2018-026505
Open access
will be evaluated across the different subgroups to search 
for similarities and differences. Reporting of qualita-
tive findings will adhere to the consolidated criteria for 
reporting qualitative research (COREQ).29
Cancer Quality of Life Questionnaire-Core 30
The European Organization for Research and Treat-
ment of Cancer Quality of Life Questionnaire (EORTC 
QLQ-C30) is a core generic questionnaire to measure 
the quality of life developed for use in clinical cancer 
trials.30 This questionnaire will be administered at T0–T4 
(see also figure 1) to measure the trajectory of the QoL 
of these patients while being treated with pixantrone. 
The EORTC QLQ-C30 is a 30-item questionnaire, with a 
global health status score, five functional scales and three 
symptom scales. The questionnaire is documented as 
having both good validity and reliability.30 The EORTC 
QLQ-C30 questionnaire and the manual are free of 
charge to academic users and Dutch translations are avail-
able. The EORTC QLQ-C30 will be obtained in Dutch, 
English, Arabic, Hindi and Turkish, due to the possible 
multicultural character of the study population.
Quality of Life Questionnaire-High Grade 29
The EORTC QLQ-NHL-LG20 (low-grade NHL) and the 
EORTC QLQ-NHL-HG29 (intermediate-grade and high-
grade NHL) are recently developed NHL-specific ques-
tionnaires.31 The development of these questionnaires 
(LG20 and HG29) are in its final (fourth) validation 
phase. The EORTC-NHL-HG29 will be administered to 
patients in this study (1) to gain some additional insight 
into disease-specific experiences and (2) to, perhaps, 
contribute to further validation of these additional 
disease-specific items. This questionnaire concerns NHL 
and treatment-related symptoms, including emotional 
impact, physical condition, symptom burden, worries, 
health and functioning and neuropathy. Items are scored 
on a 4-point Likert scale. A higher score reflects more or 
worse symptoms.31 This questionnaire will be adminis-
tered at T0–T4 (see also figure 1).
EuroQol 5 Dimensions 5 Levels
The EuroQol 5-Dimension 5-Level (EQ-5D-5L) instru-
ment was developed by a multidisciplinary group of 
researchers from seven centres across five countries.32 It 
has become one of the most widely used generic measures 
of health in Europe and has become commonly used 
in economic evaluation. The validity and reliability are 
generally supported.33 The questionnaire consists of two 
parts. The first part is a five-dimensional questionnaire. 
The five dimensions are mobility, self-care, usual activi-
ties, pain/discomfort and anxiety/depression. They each 
have five levels and together define 243 health states. The 
second part is a Visual Analogue Scale which represents 
the patients’ judgments of his or her own health state 
on a scale from 0 to 100 (100 being the best possible 
health state). Patients are classified into the EQ-5D 
by self-completion or interviewer administration. The 
EQ-5D will be administered at T0–T4 (see also figure 1).
sample size calculation
We aim to gather a sufficient number of participants to 
reach data saturation during analysis. Previous interview 
studies on patients’ decision-making and perspectives 
on healthcare have shown that a study population of 20 
participants should be sufficient in order to reach such 
saturation.34 35 After each subject, the interview will be 
transcribed as soon as possible and via this way monitored 
if new concepts arise after each patient (test for data 
saturation). Hence, data saturation is reached when no 
new concepts/information arises. The number of 20 is 
an approximation of the number obtained from litera-
ture that is required to reach data saturation.34 35 In that 
case, there is enough information to replicate the study, 
and further coding does not bring out new information. 
Additionally, we will increase the sample size if needed to 
achieve data saturation. If different themes arise between 
treatment line, age or gender, it will be discussed in the 
discussion section.
statistical analysis
Participants will be asked to fill out the, EQ-5D and the 
recently developed EORTC QLQ-30 with additional 29 
disease-specific items (QLQ HG-29). The questionnaires 
will be interpreted in accordance with the manual (refer-
ence data) after a linear transformation into a scale with 
a range of 0–100. A higher score refers to a higher stage 
of QOL. To analyse patients’ QoL trajectories (ie, how 
many shows an increase, decrease and no change) over 
time, Reliable Change Indexes (RCIs) will be calculated. 
Using the RCI, one can determine whether an individual 
change score on a measure is large enough that it is 
unlikely that this change is the consequence of measure-
ment error and can, therefore, be considered as a ‘real 
change’.’ We will calculate the RCIs with the RCI formula 
described by Jacobson and Truax.36 Difference scores on 
the QOL questionnaire will be calculated between base-
line and subsequent measures. RCI analyses cannot take 
into account variation in time. This limitation should not 
be a problem if protocol adherence is in place. Subse-
quently, patients will be divided into three categories: if 
a difference score (follow-up score—baseline score) was 
smaller than the RCI, the person was assigned to the ‘no 
change’category; if a difference score was positive and 
greater than the RCI, the person was assigned to the 
‘increase’ category; and if a difference score was nega-
tive and greater than the RCI, the person was assigned 
to the ‘decrease’ category. Finally, if available/obtained, 
data from a normative population will be compared 
with patients’ data using Mann-Whitney tests to examine 
whether RCI changes differ between the two groups.37 38 
For all analyses, we will use the Statistical Package for the 
Social Sciences V.21.0 (SPSS) and a p value less than 0.05 
will be considered statistically significant.
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dIsCussIon
We presented a protocol for studying patients’ deci-
sion-making, experiences and preferences regarding 
pixantrone treatment in heavily pretreated patients with 
relapsed or refractory DLBCL. Oncological treatment 
decision-making has become increasingly difficult for 
patients and their physicians over the past few years.39 
The quantity, complexity and adverse effects of various 
therapies make it difficult to assess costs and benefits of 
different treatment options. Therefore, it is important 
for the physicians to know the patients’ experiences and 
preferences regarding decision-making and the chosen 
treatment. Patient participation in decision-making is 
recommended because it increases control of patients 
with cancer over their well-being and results in more 
patient-oriented decisions40 and may lead to improved 
health outcomes.41 42 Results of this study will contribute to 
improving the understanding of (1) the decision-making 
process and once chosen (2) the experiences of an addi-
tional treatment with pixantrone in heavily pretreated 
patients with DLBCL.
The purpose of the present study is twofold. First, we 
want to analyse decision-making, preferences and expe-
riences of patients with DLBCL regarding pixantrone 
treatment. We want to investigate which topics are most 
relevant for patients at the beginning and during their 
treatment with pixantrone. Second, we want to evaluate 
possible changes in the trajectories of the QOL of these 
patients. The changes in QOL values will be used to 
compare; patients that respond to treatment with pixan-
trone versus those who do not respond to treatment; 
patients that start the drug treatment with pixantrone 
in an earlier disease setting (third-line treatment) versus 
those that start the treatment in a later disease setting 
(fourth line and later); and within patient differences in 
the QOL values of those that show complete response to 
pixantrone in the disease progression-free period versus 
those that show disease progression at the moment of 
disease progression. Gaining a better understanding of 
treatment-related decision-making and treatment experi-
ences could facilitate decision-making for future patients 
and doctors.
status of the trial
Due to unexpected delay in patient recruitment, we aim 
to complete the study in February 2021.
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